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Abstract:  
Cell cycle checkpoints ensure genome integrity and are frequently 
compromised in human cancers. A therapeutic strategy being explored takes 
advantage of checkpoint defects in p53 deficient tumors in order to sensitize 
them to DNA damaging agents by eliminating Chk1-mediated checkpoint 
responses. Using mouse models, we demonstrated that p21 is a key 
determinant of how cells respond to the combination of DNA damage and 
Chk1 inhibition (combination therapy) in normal cells as well as in tumors. 
Loss of p21 sensitized normal cells to the combination therapy much more 
than did p53 loss and the enhanced lethality was partially blocked by CDK 
inhibition. In addition, basal pools of 21 (p53-independent) provided p53 null 
cells with protection from the combination therapy. Our results uncover a 
novel p53-independent function for p21 in protecting cells from the lethal 
effects of DNA damage followed by Chk1inhibition. Since p21 levels are low in 
a significant fraction of colorectal tumors, they are predicted to be particularly 
sensitive to the combination therapy. Results reported in this study support 
this prediction. 
Introduction 
When exposed to DNA damaging agents, eukaryotic cells die, 
senesce or arrest their division cycles to allow time for DNA repair. The 
p53 and Chk1 proteins mediate cell cycle arrest in the G1-, S -and G2-
phases of the cell division cycle under these conditions. p53 
accomplishes this through transcriptional activation of downstream 
targets including p21 (1) whereas Chk1 promotes the ubiquitin-
mediated proteolysis of the Cdc25A protein phosphatase (2-7). TP53 is 
one of the most frequently mutated genes in human cancers and cells 
lacking a functional p53 pathway are unable to arrest in the G1 phase 
of the cell division cycle. p53 deficient tumor cells maintain their ability 
to arrest in the S- and G2-phases of the cell division cycle due to Chk1 
activity. However, they are compromised in their ability to sustain 
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these arrests (1). Importantly, Chk1 inhibitors selectively potentiate 
the cytotoxictiy of DNA damaging agents in tumor cells with 
nonfunctional p53 (8). Treating p53 deficient tumor cells with a DNA 
damaging agent or anti-metabolite followed by a Chk1 inhibitor causes 
tumor cells to move through the S- and G2-checkpoints with DNA 
damage and ultimately to die (9-13). Thus, combining Chk1 inhibitors 
with agents that induce genotoxic stress represents a therapeutic 
strategy to selectively target tumors with intrinsic checkpoint defects 
while minimizing toxicity in normal cells. Importantly, lowering Chk1 
levels with Chk1-specific siRNAs, induces bypass of both the S- and 
G2-checkpoints in p53-deficient cells thereby phenocopying effects 
observed with Chk1 inhibitors (4). These studies validate Chk1 
therapeutic target for treating p53-deficient tumors. 
While performing studies to evaluate the dependency of p53 
status on cellular responses to the therapies that combine DNA 
damage with Chk1 inhibitors, it became apparent that studies 
published to date relied on tumor cells cultured either ex vivo or as 
xenografts in rodents. Under these conditions, the individual 
contributions made by p53 mutation to experimental outcome cannot 
be directly assessed due to the plethora of additional uncharacterized 
mutations and genomic alterations present in these established cell 
lines. Furthermore, the transcriptional targets of p53 that protect cells 
from bypassing checkpoints in the presence of DNA damage and Chk1 
inhibition have not been identified. p53 maintains checkpoint 
responses through transcriptional activation of several genes including 
p21, 14-3-3σ and Gadd45 (14). p21 loss has been reported in a 
majority of colon tumors (15) and silencing of 14-3-3 σ by methylation 
has been reported in several cancers (16). Hence, it is important to 
determine how cells lacking p53 effectors respond to DNA damage 
coupled with Chk1 inhibition in order to understand which of these 
targets play dominant roles in locking down the cell cycle in the 
presence of DNA damage. To address these issues, we employed 
genetically defined mouse models (wild type, p53 null, p21 null and 
p53/p21 null mice) to assess whether DNA damage in combination 
with Chk1 inhibition selectively kills cells that are null for p53 but 
otherwise normal and to determine the role played by both basal and 
p53-induced pools of p21 in this process.  Advantages of knock-out 
mouse models include the ability to study checkpoint control in vivo 
and the ability to circumvent mutational heterogeneity associated with 
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tumor cells.  Our studies identified p53 status as a key determinant of 
how cells with DNA damage respond to Chk1 inhibition and identified a 
role for p21, both basal- and p53 induced-pools, in protecting normal 
epithelial cells and colorectal tumors from the lethal effects of DNA 
damage as a single stress or in combination with Chk1 inhibition.  
These results indicate that p21 attenuators may sensitize tumors, 
independent of their p53 status, to the lethal effects of DNA damage 
combined with Chk1 inhibition. 
Results 
DNA damage induced by irinotecan is independent of 
p53 status but enhanced by p21 loss. 
To specifically address the contribution made by p53 or p21 loss 
to the response of otherwise normal epithelial cells to the combination 
of DNA damage and Chk1 inhibition, wild type (WT) and p53 null mice 
were treated with vehicle (saline or DMSO); irinotecan (DNA damaging 
agent); UCN-01 (Chk1 inhibitor); or the combination of irinotecan and 
UCN-01. UCN-01 in combination with irinotecan is currently being 
tested in clinical trials in patients with advanced malignancies (8, 17). 
Irinotecan specifically damages S- phase cells by inducing single 
strand breaks that ultimately give rise to double strand breaks during 
the course of DNA replication. This leads to cell cycle arrest in the S- 
and G2-phases of the cell division cycle (18). Mice of 6 to 8 weeks of 
age were used as this is prior to the time when p53 null mice exhibit 
signs of lymphoma. We also focused on crypt epithelial cells of the 
small intestine owing to their rapid cell division cycles. Irinotecan 
treatment caused the accumulation of p53 (Fig. S1A) and p21 (Fig. 
S1B) in crypt epithelial cells of WT mice. Irinotecan also induced the 
accumulation of p53 in crypt epithelial cells of p21 null mice (Fig. S1A) 
and p21 accumulation was shown to be p53-dependent (Fig. S1B). 
DNA damage was assessed by monitoring for phosphorylation of 
H2AX (γH2AX) since phosphorylation of this histone variant is one of 
the earliest events observed in cells with DNA double strand breaks 
(19). γH2AX staining was observed within the proliferating 
compartment of crypts (Fig.1A) and at the base of the villi, which may 
represent differentiating progenitors that experienced DNA damage as 
they replicated in the crypt prior to their migration up into the villi 
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(denoted by arrows in panel A). As seen in Fig. 1, γH2AX staining was 
not detected in vehicle-treated controls. In contrast, ~ 42% of cells 
stained positive for γH2AX in irinotecan-treated WT and p53 null mice. 
Even higher levels of DNA damage were observed in small intestinal 
epithelial cells of p21 null mice, with ~60% of cells staining positive for 
γH2AX. 
Mice were also treated with UCN-01 alone or in combination 
with irinotecan and small intestines were isolated and analyzed for 
γH2AX. UCN-01 induced a mild DNA damage response in cells derived 
from WT and p53 null mice as ~ 2% of these cells stained positive for 
γH2AX. This DNA damage response was not unexpected, as partial loss 
of Chk1 has been shown to lead to DNA damage in other experimental 
settings (20). However, in p21 null cells the percentage of γH2AX 
positive cells increased to ~20% upon UCN-01 treatment. These data 
demonstrate that the ability of irinotecan or UCN-01, as single agents, 
to induce DNA damage in small intestinal epithelial cells is independent 
of p53 status but enhanced by p21 loss. The number of γH2AX positive 
cells was similar between cells treated with irinotecan alone or with 
irinotecan followed by UCN-01 (Fig. 1B). 
Combination therapy induces apoptosis in p53- and 
p21-null cells. 
Next, the ability of the combination therapy to cause epithelial 
cells to undergo apoptosis was determined by examining small 
intestinal crypts for the presence of either cleaved caspase-3 (Fig. 2) 
or cleaved PARP (Fig. S1C). Apoptosis was not observed in crypt 
epithelial cells from vehicle-treated WT or p53 null animals. An 
occasional crypt epithelial cell was observed to undergo apoptosis in 
vehicle treated p21 null mice. Irinotecan induced apoptosis in ~1 cell 
per 2 crypts in mice that were WT for p53 (WT mice and p21 null 
mice) but not significantly in p53 null mice. As a single agent, UCN- 01 
did not induce apoptosis in WT or p53 null cells but a small number of 
p21 null cells were consistently observed to undergo apoptosis in 
vehicle and UCN-01 treated animals (Fig. 2B). Importantly, the 
combination therapy was able to induce apoptosis of p53 null cells and 
the effects were even more striking in p21 null cells. We also tested a 
second more selective Chk1 inhibitor, AZD7762 (13) for its ability to 
potentiate the effects of irinotecan in p53 and p21 null crypt epithelial 
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cells. As seen in Fig. S1D, AZD7762 had some activity as a single 
agent but greatly enhanced the ability of irinotecan to induce crypt 
epithelial cells lacking either p53 or p21 to undergo apoptosis. 
Bypass of DNA damage checkpoint in cells null for 
either p53 or p21. 
It has been proposed that DNA damage coupled with Chk1 
inhibition induces cells to bypass DNA damage checkpoints resulting in 
mitotic catastrophe and cell death. Therefore, we monitored the ability 
of irinotecan to induce cell cycle arrest and UCN-01 to abrogate this 
arrest. Irintoecan was expected to arrest cells in the S and G2 phases 
of the cell division cycle thereby reducing BrdU incorporation and 
leading to higher levels of Geminin, a protein specifically expressed in 
the S- and G2-phases of the cell cycle (21). In addition levels of 
phosphorylated histone H3 (phistone H3) a mitotic marker (22, 23) 
were expected to be lower in cells with DNA damage due to G2 cell 
cycle arrest. Crypt epithelial cells of the small intestines have a high 
proliferative index in vehicle- treated animals, ~35-40% of cells 
stained positive for BrdU (Fig. S2) and Geminin (Fig. 3A). As expected, 
there was significant increase in the number of Geminin positive cells 
(Fig. 3A) as well as a significant decrease in both the number of BrdU 
positive (Fig. S2) and phistone H3 positive (Fig. 3B, C) cells in 
irinotecan-treated mice, indicative of cell cycle arrest. However, 
irinotecan was less effective at inducing cell cycle arrest in p21 null 
cells compared to WT and p53 null cells, as shown by the higher 
percentage of p21 null cells staining positive for BrdU (Fig. S2) and 
phistone H3 (Fig. 3B, C) in the presence of DNA damage. At baseline, 
there were 50% more p21 null cells that stained positive for phistone 
H3 compared with WT and p53 null cells (Fig. 3B, C). The higher 
mitotic index in intestinal epithelial cells lacking p21 indicates that p21 
loss perturbs normal cell cycle regulatory circuits. 
It was predicted that when UCN-01 was administered to 
irinotecan-treated animals, checkpoint bypass would be observed in 
p53 null but not p53 WT cells resulting in a reduction in Geminin 
staining coincident with an increase in phistone H3 staining. As seen in 
Fig. 3, checkpoint bypass was observed in p53 null but not WT cells. 
Interestingly, p21 null cells were even more sensitive than p53 null 
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cells to the combination treatment as indicated by the higher numbers 
of phistone H3 staining cells (Fig. 3B, C). 
We next asked whether there was a coincidence of checkpoint 
bypass and apoptosis in p53 null cells exposed to the combination 
therapy. This was accomplished by looking for crypt epithelial cells 
that co-stained for both phistone H3 and cleaved caspase-3 (Fig. S3A, 
B). ~ 2% of epithelial cells in crypts of p53 null mice and 8% in crypts 
of p21 null mice stained positive for both phistone H3 and cleaved 
caspase-3 indicating that these cells bypassed the G2 DNA damage 
checkpoint, entered into mitosis and engaged the apoptotic pathway 
(Fig. S3B). However, there were many more cleaved caspase 3 
positive cells than phistone H3 positive cells, suggesting that either 
apoptosis occurred independent of checkpoint bypass in these cells or 
that the timing of organ harvest was not optimal to capture co-stained 
cells. 
Cdk activation is required for combination therapy to 
induce checkpoint bypass and apoptosis. 
Next, the phosphorylation status of Cdk1/2 was examined in 
lysates prepared from the small intestines of treated animals (Fig. 4A). 
Tyrosine 15-phosphorylation (pY15) inhibits the enzymatic activity of 
Cdk1/2 (24) and therefore can be used to indirectly assess Cdk activity 
under a variety of conditions. As expected pY15 levels increased upon 
irinotecan-treatment in each genotype, indicative of Cdk inhibition in 
response to DNA damage (lanes 2, 6, 10) and Cdk1/2 became partially 
dephosphorylated on Y15 when mice were subsequently treated with 
UCN-01 (lanes 3, 7, 11).  This was an expected result because UCN-01 
inhibits Chk1 causing Cdc25A phosphatase levels to rise resulting in 
Cdk1/2 dephosphorylation (4). Although the combination treatment 
resulted in Cdk1/2 dephosphorylation in all cases, checkpoint bypass 
and apoptosis were only observed in crypt epithelial cells lacking p53 
or p21 (Fig. 2, 3). Next, experiments were carried out to determine if 
Cdk activity is needed in order for the combination therapy to induce 
apoptosis (Fig. 4B, C). This was accomplished by treating mice with 
purvalanol A, a potent Cdk inhibitor (25). A reduction of the number of 
mitotic cells was observed in the small intestines of purvalanol A-
treated mice demonstrating that the drug was bioavailable (Fig. S3C, 
D). Mice were subjected to the combination therapy followed by 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Oncogene, Vol. 32, No. 5 (January 2013): pg. 577-588. DOI. This article is © Nature Publishing Group (Macmillan 
Publishers Limited) and permission has been granted for this version to appear in e-Publications@Marquette. Nature 
Publishing Group (Macmillan Publishers Limited) does not grant permission for this article to be further 
copied/distributed or hosted elsewhere without the express permission from Nature Publishing Group (Macmillan 
Publishers Limited). 
8 
treatment with either vehicle or purvalanol A and small intestinal 
crypts were examined for cleaved caspase 3. There was a significant 
decrease (~50%) in the number of apoptotic (Fig. 4B, C) crypt 
epithelial cells in purvalanol A treated animals compared with vehicle 
treated controls. Thus, the combination treatment induced checkpoint 
bypass and apoptosis, at least in part, through Cdk activation. 
Loss of p21 enhances combination treatment induced 
apoptosis in cells lacking p53.  
Crypt epithelial cells null for p21 but wild-type for p53 exhibited 
a robust apoptotic response to the combination therapy (Fig. 2) 
relative to p53 null cells that retained basal pools of p21. As expected, 
p21 was not induced by DNA damage in the absence of p53 (Fig S1B). 
The enhanced sensitivity of p21 null cells relative to p53 null cells to 
the combination therapy led us to ask if p53-independent (basal) pools 
of p21 played a role in protecting cells from the lethal effects of the 
combination therapy. To do this, double knockout mice lacking both 
p21 and p53 were treated with vehicle, irinotecan, UCN-01 or the 
combination therapy (Fig. 5 and Fig. S4A-C). Approximately 50% of 
vehicle- treated cells stained weakly for γH2AX indicating a significant 
amount of DNA damage in the absence of exogenous genotoxic and 
irinotecan treatment increased both the number and intensity of 
γH2AX positive cells (Fig. 5A, B and Fig. S4A, B). As expected, levels 
of tyrosine-phosphorylated Cdk rose in cells of irinotecan-treated 
animals and fell in cells of mice treated with either UCN-01 alone or 
the combination therapy (Fig. 5C). These results demonstrated that 
the Chk1 pathway was active in these cells and the drugs were 
bioavailable in the small intestinal crypts of p53/p21 null animals. 
Similar to p21 null cells, irinotecan treatment did not significantly 
reduce BrdU incorporation (Fig. S4C, D) in p53/p21 double null cells, 
suggestive of intrinsic checkpoint defects in these cells. Importantly, 
the combination therapy induced checkpoint bypass in p53/p21 double 
null cells as evidenced by the increase in the number of mitotic cells 
observed in cells exposed to the combination treatment compared with 
cells exposed to irinotecan alone (Fig 5D, E). In addition, the 
combination therapy was capable of driving p53/p21 double null cells 
into apoptosis (Fig. 5F, G) but not to the same degree as that 
observed in cells null for p21 but WT for p53 (Fig. 2B). These results 
demonstrated that both p53- dependent and -independent 
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mechanisms operate to induce apoptosis under these conditions and 
that p53-independent mechanisms were significantly enhanced in the 
absence of basal pools of p21. These results reinforce the conclusion 
that basal pools (p53 independent) of p21 provide a protective 
function in p53 null cells. 
Loss of p21 enhances ability of combination therapy to 
drive p53 deficient colorectal tumor cells into apoptosis 
Taken together, our results suggested that p21 deficient (p53 
proficient) cells should be more susceptible to cell killing by 
combination therapies than p53-deficient (p21 proficient) cells. To test 
this and to determine the therapeutic efficacy of our findings, we 
employed an orthotopic colon cancer model whereby parental and 
mutant HCT116 tumor cells (1) were implanted directly into the cecum 
of immunocompromised mice as described previously (26). Prior to 
establishing the orthotopic xenografts, parental and p53 null HCT116 
cells were transfected with plasmids expressing control (Ctrl) shRNAs 
or p21-specific shRNAs followed by selection in puromycin.  Although 
HCT116 cells null for p21 have been reported (27), we detected 
endogenous p21 in these cells both at the protein and mRNA levels 
(data not shown). As seen in Fig. 6A, parental HCT116 cells 
transfected with Ctrl shRNAs maintained an intact p53 DNA damage 
signaling pathway as indicated by the accumulation of p53 and p21 
upon UV-treatment. We were able to achieve knockdown (KD) of p21 
in p53 null HCT116 cells (Fig. 6B, lane 3). Interestingly, when parental 
HCT116 cells (p53 WT) were knocked down for p21 and selected in 
puromycin, we observed a concurrent loss of p53 protein (Fig. S4E). 
This was not observed in parental HCT116 cells transiently transfected 
with plasmids encoding p21-specific shRNAs (Fig. S4F). Thus, p53 
expression was selected against in HCT116 tumor cells lacking p21 
function and as a result we were unable to obtain HCT116 cells that 
were WT for p53 but knocked down for p21. 
Next, HCT116 cells (parental, p53 null and p53 null/p21 KD) 
were engineered to express a reporter gene encoding click beetle red 
luciferase, cells were implanted into the cecum of recipient mice and 
bioluminescence imaging was employed to demonstrate successful 
implantation of tumor cells (Fig. 6C). Mice were then exposed to either 
vehicle, irinotecan, AZD7762 (selective Chk1 inhibitor) or the 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Oncogene, Vol. 32, No. 5 (January 2013): pg. 577-588. DOI. This article is © Nature Publishing Group (Macmillan 
Publishers Limited) and permission has been granted for this version to appear in e-Publications@Marquette. Nature 
Publishing Group (Macmillan Publishers Limited) does not grant permission for this article to be further 
copied/distributed or hosted elsewhere without the express permission from Nature Publishing Group (Macmillan 
Publishers Limited). 
10 
combination of irinotecan and AZD7762. Tumors were removed and 
analyzed for phistone H3 (Fig. 6D) and cleaved caspase 3 (Fig. 6E, F). 
A significant increase in phistone H3 staining was observed in p53 null 
and p53 null/p21 KD cells compared to parental cells following 
exposure to the combination therapy. This indicates that cells deficient 
in p53 or both p53 and p21 bypassed the G2 DNA damage checkpoint. 
The combination therapy induced significantly more apoptosis in cells 
lacking both p53 and p21 compared with control and p53 null cells 
(Fig. 6E, F). Finally, p21 levels were restored in p53 null/p21 KD 
HCT116 cells, cells were implanted into the cecum of recipient mice 
and mice were treated as outlined above. As seen in Figure S5, 
restoration of p21 in p53 null/p21 KD cells significantly reduced their 
sensitivity to the combination therapy. These results validated the 
specificity of the p21-shRNA and confirmed that basal pools of p21 
provide partial protection to p53-deficient tumor cells from the lethal 
effects of therapies that combine DNA damage with Chk1 inhibition. 
Discussion 
The development of anti-cancer regimens that take advantage 
of the molecular differences between normal and cancer cells is highly 
desirable. TP53 is one of the most frequently mutated genes in human 
cancers and, as such, there is great interest in finding anti-cancer 
regimens that selectively target p53 deficient tumors. Importantly, 
Chk1 inhibitors such as UCN-01 and AZD7762 selectively potentiate 
the cytotoxicity of DNA damaging agents in tumor cells with 
nonfunctional p53 (11, 13, 28) and are currently being tested in 
several clinical trials (8). In our study, we circumvented the 
heterogeneity of transformed cells, and used mouse models to address 
the contribution made by loss of p53 and its effector p21 in sensitizing 
cells to the combination of DNA damage and Chk1 inhibition. 
Irinotecan as a single agent induced 10 fold more apoptosis of small 
intestinal epithelial cells in WT animals compared with cells from p53 
null animals. This was in spite of the fact that levels of DNA damage 
induced by irinotecan were similar in WT and p53 null cells.  Whereas 
irinotecan as a single agent was ineffective at driving p53 null cells 
into an apoptotic cell death, we found that treatment with Chk1 
inhibitors was capable of enhancing apoptosis in response to irinotecan 
in these cells. This result unequivocally demonstrated that p53 is a 
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significant determinant of how cells respond to DNA damage followed 
by Chk1 inhibition. 
Intriguingly, crypt epithelial cells lacking p21 sustained more 
DNA damage than their WT or p53 null counterparts following 
exposure to irinotecan and were more susceptible to cell killing by the 
combination therapy. Given the large number of p53- regulated genes, 
it was not necessarily expected that the loss of a single target (p21) 
would have such a profound effect.  These results demonstrated that 
Chk1 together with p53, largely through its downstream effector p21, 
protects crypt epithelial cells from the DNA damaging effects of 
irinotecan. In addition, this study demonstrates that p53- independent 
(basal) pools of p21, together with Chk1, protect crypt epithelial cells 
from the DNA damaging effects of irinotecan. Rodriguez et al. (2006) 
reported that HCT116 cells lacking p21 were sensitive to the 
combination of excess thymidine and Chk1 inhibition and they noted 
that p21 is induced when Chk1 is inhibited independent of p53 status. 
However, their study did not test the importance of p21 induction in 
p53 null cells by deleting it nor did they investigate the mechanism of 
cell death. Here we report the consequences of deleting p21 (in p53 
null mice) and knocking down p21 (in p53 null tumor cells). 
Our results demonstrated that basal pools of p21 (p53-
independent) protected crypt epithelial cells from the DNA damaging 
effects of irinotecan as both p21 null and p21/p53 null cells exhibited 
higher levels of DNA damage following exposure to irinotecan than did 
cells from WT animals or cells from mice that were null for p53 but WT 
for p21 (Fig1B, 5A). Despite similar levels of DNA damage, a higher 
fraction of crypt epithelial cells null for p21 (p53 WT) underwent 
apoptosis compared with crypt epithelial cells null for both p21 and 
p53. This suggests that tumors that are proficient in p53 signaling and 
have low levels of p21 will be the most susceptible to combination 
therapies that combine DNA damage with Chk1 inhibition due to their 
ability to induce p53-dependent and -independent forms of apoptosis. 
In addition, apoptosis observed in treated cells null for both p53 and 
p21 was higher than that that observed in treated cells null for p53 but 
WT for p21. Thus, combining p21 antagonists with the combination 
therapy (DNA damage and Chk1 inhbition) is expected to further 
sensitize p53 deficient tumors to the combination therapy. 
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p21 has many functions that might explain how p53-
independent pools protect cells from the genotoxic effects of DNA 
damaging agents and Chk1 inhibitors. p21 inhibits cell cycle 
advancement by binding to and inhibiting CDKs (15). In addition to 
regulating cell cycle progression, p21 binds to proliferating cell nuclear 
antigen (PCNA), a DNA polymerase δ processivity factor, thereby 
blocking processive DNA synthesis (29).  The cytoplasmic pool of p21 
has been shown to regulate apoptosis by binding to and inhibiting the 
activity of proteins that induce apoptosis, including procaspase 3, 
caspases 8 and 10, and the protein kinases SAPK and ASK1 (30). 
Paradoxically, low levels of p21 promote assembly of cyclin D-CDK4/6 
complexes and in this capacity has a positive role in promoting cell 
cycle advancement (31). In order to distinguish between the these 
diverse functions of p21 (Cdk regulator versus apoptotic regulator), we 
treated mice with the Cdk inhibitor purvalanol A. Results demonstrated 
that p21 exerts its protective effect, at least in part, through its ability 
to inhibit Cdk activation (Fig. 4C). 
We also observed that crypt epithelial cells that were null for 
p53 but otherwise normal exhibited more modest apoptotic responses 
to the combination therapy than did p53 deficient cancer cells. In 
addition, experiments performed with a variety of cultured p53-
deficient tumor cells have reported 50 to 100 fold more cell death with 
the combination therapy than with the DNA damaging alone (18, 32, 
33). We measured a ~10 fold difference in the number of p53 null 
small intestinal epithelial cells undergoing apoptosis in response to the 
two treatment regimens. The differential response of non- transformed 
p53 mutant epithelial cells compared with transformed p53 mutant 
tumor cells to the combination therapy may be due to oncogenic stress 
present in p53 mutant tumor cells. Oncogenic stress activates the 
ATR/Chk1 pathway (34-36) and tumor cells depend on this signaling 
pathway to maintain some semblance of genome stability (37). 
HCT116 cells, used in this study, contain homozygous mutations in the 
mismatch repair gene hMLH1 and this may also contribute to their 
sensitivity to the combination therapy. Thus, the differential response 
of p53 mutant normal cells versus p53 mutant tumor cells was likely 
due to the presence of additional mutations present in tumor cells that 
make them more vulnerable to cell death when subjected to DNA 
damage followed by Chk1 inhibition and points to the usefulness of 
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this therapeutic strategy in treating cancers lacking a functional p53 
pathway. 
In conclusion, this study demonstrates that p21 status is a 
significant determinant of how cells with DNA damage respond to Chk1 
inhibition and that p21 provides a protective effect in response to 
combination therapies, in both p53 proficient and deficient 
backgrounds. A major debilitating side effect of chemotherapy is GI-
toxicity. Here we show that p21 protects intestinal epithelium from the 
toxicity associated with DNA damage and that Chk1 inhibition 
sensitizes p21 deficient tumors to DNA damaging agents. This is 
expected to provide a therapeutic window that facilitates killing of p21 
deficient tumor cells while at the same time limiting G1 toxicity. 
Materials and Methods  
Additional information for the methods and materials used can 
be found in Supplemental Methods. 
All animal experiments described in this study were carried out 
in strict accordance with the guidelines recommended for care and use 
of laboratory animals by the National Institutes of Health (NIH, USA). 
The Animal Studies Committee at Washington University (St. Louis) 
approved all animal protocols used in this study. 
Genotyping Trp53, Cdkn1a [p21WAF1/CIP1] mutant mice 
Trp53 mutant mice (B6.129S2-Trp53tm1T4j/J, stock # 002102) 
and Cdkn1a mutant mice (B6;129S2-Cdkn1atm1Tyj/J, stock# 003263) 
were obtained from The Jackson Laboratory. 6 to 8 week old 
Trp53+/+Cdkn1a+/+ (Wild type-WT), Trp53-/- littermates and Cdkn1a-/- 
mice were used in this study. The Trp53+/- mutant mice and Cdkn1a-/- 
mice were bred to generate the double knockout mice (Trp53-/- 
Cdkn1a-/-). 6-14 week old Trp53-/- Cdkn1a-/- mice were used in this 
study. 
Treatment regimen 
Drugs and vehicles were administered to mice via an 
intraperitoneal (IP) route. Vehicle treated mice received 0.9% saline 
on Day 1; 24h later (Day 2) they received 30% dimethyl sulphoxide 
(DMSO) and were sacrificed 6h later. For single drug treatments, mice 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Oncogene, Vol. 32, No. 5 (January 2013): pg. 577-588. DOI. This article is © Nature Publishing Group (Macmillan 
Publishers Limited) and permission has been granted for this version to appear in e-Publications@Marquette. Nature 
Publishing Group (Macmillan Publishers Limited) does not grant permission for this article to be further 
copied/distributed or hosted elsewhere without the express permission from Nature Publishing Group (Macmillan 
Publishers Limited). 
14 
were injected with either 100 mg/kg irinotecan (Hospira, diluted in 
saline) and sacrificed 24h later, or 5 mg/kg UCN-01 (Sigma, dissolved 
in 30% DMSO) and sacrificed 6h later. For the combination treatment, 
mice were injected with 100 mg/kg irinotecan on Day 1; 24h later 
(Day 2) they received 5 mg/kg UCN-01 and were sacrificed 6h later. 
To inhibit Cdk1 in vivo, mice received 100 mg/kg irinotecan on Day 1; 
24h later (Day 2) they were injected with 5 mg/kg UCN-01; 1h after 
receiving UCN-01, mice were injected with 68 mg/kg purvalanol A 
(Tocris) or vehicle (PEG400: DMSO 50:50) and sacrificed 5h later (Fig 
4C). To ensure the bioavailability of purvalanol A and its ability to 
inhibit intestinal cell proliferation, animals were injected with two 
doses of the drug. 68 mg/kg purvalanol A or vehicle (PEG 400: DMSO 
50:50) was injected followed by a second dose of purvalanol A (34 
mg/kg) or vehicle 1.5h later and sacrificed 1h after the second dose 
(Fig S3C). The second dosing was administered because the half-life of 
purvalanol A in mice is ~1h (38).  For AZD7762 treatment, mice 
received either 20 mg/kg AZD7762 (Axon Medchem) or vehicle 
(11.3% 2-hydroxypropyl-β- cyclodextrin diluted in saline) and were 
sacrificed 5h later. For the combination treatment, mice were injected 
with 100 mg/kg irinotecan on Day 1, and 24h later (Day 2) they were 
injected with 20 mg/kg AZD7762 and sacrificed 5h later. 
Immunohistochemistry (IHC) and immunofluorescence 
(IF) 
All paraffin embedded intestinal sections were incubated with 
the following antibodies: serine139 phosphorylated H2AX (γH2AX, Cell 
Signaling Technology), Geminin (Santa Cruz), BrdU (Serotec), serine 
28 phosphorylated histone H3 (Sigma-Aldrich), cleaved caspase-3 and 
cleaved PARP (Cell Signaling Technology). To assay for BrdU 
incorporation, mice were injected with BrdU (Amersham) according to 
the manufacturer’s recommendations (2 ml per 100 g body weight) 
and sacrificed 30 min later. 
Cell culture and transfection 
Parental and p53 null HCT116 cells (human colon carcinoma 
cells) were transfected with a pcDNA plasmid expressing Click Beetle 
Red Luciferase (CBRluc) reporter linked to EGFP. Clones stably 
transfected with CBRluc-EGFP were selected by screening for zeocin 
(Invitrogen) resistance. CBRluc-EGFP expressing parental and p53 null 
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HCT116 cells were transfected with pLKO.1 vector expressing either a 
p21 targeted shRNA or control shRNA directed against firefly luciferase 
(provided by the RNAi consortium of Broad institute and Children's 
discovery institute at Washington University). Stably transfected 
clones were selected by screening for puromycin (Invitrogen) 
resistance. To ensure stable knockdown, cells expressing p21 shRNA 
or control shRNA were screened by Western blotting. 
Implantation and treatment of orthotopic colon tumors 
For establishing orthotopic colon tumors, 1.3 x 106 cells were 
resuspended in 30 µl DMEM culture medium (GIBCO) and injected into 
the cecal wall of immunocompromised NOD/SCID gamma mice (The 
Jackson Laboratory, NOD.Cg- Prkdcscid Il2rgtm1Wjl/SzJ stock# 
005557). Bioluminescence imaging was performed on days 3 and 7 
post injection to monitor success of tumor implantation and growth. 
Bioluminescent images were acquired using the IVIS Lumina (Caliper). 
Images were analyzed using LivingImage software (Xenogen). Seven 
to nine days post implantation; mice were subjected to the following 
treatment schedule: t = 0h (Day 1) vehicle/irinotecan; t = 18h (Day 
2) vehicle/AZD7762; t = 26h (Day 2) vehicle/AZD7762; t = 50h (Day 
3) vehicle/irinotecan; t = 68h (Day 4) AZD7762/vehicle and mice were 
sacrificed at t = 73h (Day 4). The following drug doses were used: 100 
mg/kg irinotecan and 25 mg/kg AZD7762. 0.9% saline and 11.3% 2-
hydroxypropyl-β-cyclodextrin diluted in saline were used as the vehicle 
controls for irinotecan and AZD7762, respectively. 
Microscopy 
For IHC analysis, images were captured using an Olympus BX51 
microscope carrying an Olympus DP-71 camera. Images were 
processed using DP-BSW software (Olympus). For analysis of IF 
staining, images were captured using an Olympus BX-61 microscope 
carrying a digital camera (C10600, Hamamatsu). Fluorescent images 
were processed using Microsuite Biological Suite analysis software 
(Olympus). 
Western blotting 
Intestines were isolated from treated mice and processed as 
described in supplemental methods. 150 µg of total protein from 
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intestinal lysates were loaded in each lane and probed with the 
following antibodies: tubulin (1:1000, Sigma-Aldrich), p53 (1:500, 
Leica Microsystems), GAPDH (1:2000, Imgenex), p21 (F-5, 1:1000, 
Santa Cruz), phospho- Cdk1 Tyrosine 15 (1:750, Santa Cruz), and 
Cdk1-total (1:750, Santa Cruz). For Western blotting using HCT116 
cell lysates, the following antibodies were used: p53 (sc-126, 1:1000, 
Santa Cruz), p21 (1:500, BD Biosciences,), tubulin (1:2500, Cell 
Signaling Technology), actin (1:6000, Sigma), GAPDH (1:4000, 
Imgenex). 
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Figure legends 
Figure 1. DNA damage induced by irinotecan is independent of p53 
status but enhanced by p21 loss. (A) Small intestinal crypts isolated from 
wild-type (WT), p53 null and p21 null mice that had been subjected to the 
indicated treatments were examined by IHC for γH2AX (brown) and nuclei 
were counterstained with hematoxylin (blue). Scale bar =100 µM. Arrows 
indicate γH2AX positive cells that migrated up into the villi. (B) γH2AX 
positive nuclei were counted in images similar to those shown in panel A. 
Three mice were evaluated for each treatment group and a total of 250-400 
crypt nuclei were scored per treatment group. Data are presented as mean 
+/- SEM. Asterisks indicate significantly different using one-way ANOVA. *p 
between 0.01 and 0.05; **p between 0.01 and 0.001; ***p< 0.001. 
Statistical significance for comparisons between irinotecan and the 
combination treatment across genotypes is indicated in Table S1. 
Figure 2. Loss of p53 or p21 sensitizes crypt epithelial cells to 
combination therapy. (A) Small intestinal crypts isolated from treated wild-
type (WT) mice or mice null for either p53 or p21 were examined by IHC for 
cleaved caspase-3 (CC3) (brown) and nuclei were counterstained with 
hematoxylin (blue). Scale bar =100 µM. (B) The number of cells staining 
positive for CC3 was determined in a total of 50 crypts per treatment group 
(n = 3 to 5 mice per treatment group). Data are presented as mean +/- SEM. 
Asterisks indicate significantly different using a one way ANOVA. **p between 
0.01 and 0.001, ***p < 0.001. Statistical significance for comparisons 
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between irinotecan and the combination treatment across genotypes is 
indicated in Table S1. 
Figure 3. Combination treatment induces checkpoint bypass in crypt 
epithelial cells null for p53 or p21. (A) Small intestinal crypts isolated 
from treated wild-type (WT) mice or mice null for either p53 or p21 were 
examined for Geminin by immunofluorescent staining. Right panel illustrates 
Geminin positive cells in small intestinal crypts of irinotecan treated WT mice. 
Geminin (green); nuclei (blue, DAPI). Scale bar = 50 µM. Percentage of crypt 
epithelial cells staining positive for Geminin was determined by scoring 200 to 
300 nuclei per mouse (n = 3 to 5 mice per treatment group). Data are 
presented as mean +/- SEM. Asterisks indicate significantly different as 
determined by a one-way ANOVA. *p between 0.01 and 0.05; **p between 
0.01 and 0.001; ***p< 0.001. Significant difference was also observed 
between the combination treatments for WT compared to p53 null with p< 
0.001and WT compared to p21 null with p< 0.001 (B) Small intestinal crypts 
isolated from treated mice were stained for phosphohistone H3 (pHH3) and 
the number of pHH3 positive cells per 75 crypts per mouse (n = 3 to 4 mice 
per treatment group) was determined (panel C). pHH3 (red); nuclei (blue, 
DAPI). Scale bar = 200 µM. Data are presented as mean +/- SEM. Asterisks 
indicate significantly different by a one-way ANOVA. *p between 0.01 and 
0.05; **pbetween 0.01 and 0.001; ***p< 0.001. Statistical significance for 
pHH3 comparisons between irinotecan and the combination treatment across 
genotypes is indicated in Table S1. 
Figure 4. Effects of Cdk inhibition on ability of combination therapy to 
induce checkpoint bypass and apoptosis in crypt epithelial cells 
lacking p21 or p53. (A) Small intestines were isolated from treated WT mice 
(lanes 1-4), p53 null (lanes 5-8) and p21 null mice (lanes 9-12), and 
analyzed by Western blotting for Cdk1 (total levels), Cdk1 phosphorylated on 
tyrosine 15 (pY15) and tubulin. (B) Small intestinal crypts isolated from 
treated mice were examined for cleaved caspase-3 (CC3) (brown) and nuclei 
were counterstained with hematoxylin (blue) by IHC. Scale bar = 50 µM. (C) 
Cells staining positive for CC3 were counted in 50 crypts per mouse per 
treatment group (3 to 4 mice per treatment group). Data are presented as 
mean +/- SEM. Asterisks indicate significantly different using a two-tailed T-
test. *p between 0.01 and 0.05, ***p < 0.001. 
Figure 5.  Basal levels of p21 levels protect small intestinal epithelial 
cells from lethal effects of combination therapy. (A) Small intestinal 
crypts isolated from treated mice null for both p53 and p21 were examined by 
IHC for γH2AX (brown) and nuclei (hematoxylin, blue). Scale bar = 50 µM. 
(B) Three mice were evaluated for each treatment group and a total of 150-
200 crypt nuclei were scored for γH2AX positive nuclei in each treatment 
group. (C) Small intestines were isolated from treated mice and analyzed by 
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Western blotting for Cdk1 (total levels), Cdk1 phosphorylated on tyrosine 15 
(pY15) and tubulin. (D) Small intestinal crypts isolated from treated mice 
were stained for phistone H3 (pHH3, red) and nuclei (blue, DAPI) and (E) the 
number of pHH3 positive cells per 75 crypts was determined. Scale bar = 100 
µM. Three mice were analyzed per treatment group. (F) Small intestinal 
crypts isolated from treated mice were examined for cleaved caspase-3 (CC3) 
(brown) and nuclei (hematoxylin, blue) by IHC. Scale bar = 100 µM. (G) The 
number of cells staining positive for CC3 was determined by counting CC3 
positive cells in a total of 50 crypts per treatment group (n = 3 mice per 
treatment group). Data in panels B, E and G is presented as mean +/- SEM. 
Asterisks indicate significantly different by a one-way ANOVA.*p between 
0.01 and 0.05; **p between 0.01 and 0.001; ***p< 0.001. Statistical 
significance for comparisons between irinotecan and the combination 
treatment across genotypes is indicated in supplementary Table S1. 
Figure 6. p53 null orthotopic colon tumors lacking basal p21 undergo 
profound cell death in response to combination therapy. (A) Parental 
HCT116 cells stably expressing click beetle red luciferase (CBRLuc) and 
control (Ctrl) shRNAs were either mock irradiated or exposed to 20 J/m2 UV. 
Lysates were prepared and analyzed by Western blotting 24 h later. (B) 
Lysates prepared from p53 null HCT116 cells stably expressing CBRLuc and 
either Ctrl or p21 specific shRNAs were analyzed by Western blotting. (C) p53 
null HCT116 cells stably expressing CBRLuc and Ctrl shRNAs were implanted 
into the cecum of immunocompromised mice. One week later, mice were 
injected with D-luciferin and subjected to bioluminescence imaging using the 
IVIS Lumina system (Caliper). Representative images of mice are shown. 
Photon flux is indicated by pseudocolored heatmap and tumor specific 
luciferase activity was measured by drawing a rectangular region of interest 
(ROI) as indicated (units: photons/sec x 106). (D) Treated mice engrafted 
with the indicated HCT116 cell lines were sacrificed and tumors were isolated 
and analyzed for pHH3 by immunofluorescence. Total and pHH3 positive cells 
were determined in three separate fields per tumor section per treatment 
group (n = 3 mice per treatment group). (E) Treated mice engrafted with the 
indicated HCT116 cell lines were sacrificed and tumors were isolated and 
analyzed by IHC for CC3 (brown) and nuclei were counterstained with 
hematoxylin (blue). (F) Total and CC3 positive cells were determined in four 
to five separate fields per tumor section per treatment group (n = 3 to 4 mice 
per treatment group). Scale bar =100 µM. Data in panels D and E is 
presented as mean +/- SEM. Asterisks indicate significantly different by a 
one-way ANOVA. *p = 0.01 to 0.05, **p= 0.01 to 0.001. 
Figure 7. Model to explain the differential sensitivity of p53 and p21 
null cells to DNA damage alone or combined with loss of Chk1 
activity. (A) Small intestinal epithelial cells responded to irinotecan by 
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activating a p53- dependent response pathway leading to the transcriptional 
activation of genes encoding cell cycle arrest (p21 and 14-3-3 ) and 
apoptotic (PUMA) proteins. Activation of cyclin- dependent protein kinases 
(Cdks) was prevented by at least two mechanisms including p21 binding and 
tyrosine phosphorylation (pY). Two pools of p21 were present in these cells 
(those that existed prior to irinotecan-treatment (basal or p53-independent, 
teal colored) and those that accumulated after irinotecan-treatment (p53-
induced, salmon colored). Although equivalent levels of DNA damage were 
observed in p53 proficient and null cells, only p53 proficient cells underwent 
apoptosis, due to the accumulation of cell death proteins such as PUMA. In 
p21 null cells, DNA damage failed to efficiently inactivate Cdks due to loss of 
p21 (both p53-dependent and –independent pools) and cells did not 
efficiently arrest their cell division cycles under these conditions. Higher levels 
of DNA damage and therefore apoptosis (p53-dependent) were observed 
under these conditions. Cells lacking both p21 and p53 sustain high levels of 
DNA damage (due to loss of basal and induced pools of p21) but underwent 
less apoptosis (due to loss of p53- dependent apoptosis). 
(B) Treating small intestinal epithelial cells with irinotecan followed by a Chk1 
inhibitor, resulted in the tyrosine dephosphorylation of Cdks due to the 
accumulation of the Cdc25A phosphatase (4). However, both basal and 
induced p21 pools were able to maintain low Cdk activity under these 
conditions. Thus, Chk1 inhibition did not synergize with irinotecan to induce 
more DNA damage in normal intestinal epithelial cells. However, in p53 null 
cells treated with the combination therapy, loss of tyrosine phosphorylation 
coupled with loss of p21 synergized to induce apoptosis. Finally, levels of 
apoptosis were even higher in cells lacking p21 because these cells lack Cdk 
tyrosine phosphorylation as well as basal and induced pools of p21. 
Supplementary Data:  
Supplemental Figure Legends 
Figure S1. Impact of p53 and p21 status on response of crypt 
epithelial cells in small intestines to various treatment regimens (a) 
Lysates prepared from small intestines of treated WT (lanes 1-4) and p21 null 
(lanes 5-8) mice and of an untreated p53 null mouse (lane 9) were subjected 
to Western blotting with the indicated antibodies. (b) Lysates prepared from 
the small intestines of treated WT (lanes 1-4) and p53 null (lanes 5-8) mice 
were subjected to Western blotting with the indicated antibodies. (c) Small 
intestinal crypts isolated from treated mice of the indicated genotypes were 
examined for cleaved PARP by IHC. The number of cells staining positive for 
cleaved PARP was determined in 50 crypts per treatment group (n = 3 to 4 
mice per treatment group). (d) Small intestinal crypts isolated from treated 
mice of the indicated genotypes were examined for cleaved caspase-3 (CC3) 
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by IHC. Values for irinotecan and vehicle treated groups were utilized from 
figure 2b. The number of cells staining positive for CC3 was determined in a 
total of 50 crypts per treatment group (n = 3 to 4 mice per treatment group). 
Data is presented as mean +/- SEM in panels c and d. Asterisks indicate 
significantly different using a two-tailed T-test. *p between 0.01 and 0.05, 
**p between 0.01 and 0.001. 
Figure S2. Replication checkpoint compromised in crypt epithelial 
cells null for p21. (a) Treated mice of the indicated genotypes were injected 
with BrdU 30 min prior to sacrifice. Small intestines were isolated and 
analyzed by immunofluorescent staining for BrdU (red). Nuclei (blue) were 
stained with DAPI. Scale bar = 100 µM. (b) Percentage of crypt epithelial cells 
staining positive for BrdU was determined by scoring 200 to 300 nuclei per 
mouse (n = 3 to 4 mice per treatment group). Data is presented as mean +/- 
SEM in panel B. Asterisks indicate significantly different using a two-tailed T-
test, **p = 0.01 to 0.001. 
Figure S3. Coincidence of pHH3 and CC3 staining in crypt epithelial 
cells of treated mice. (a) Small intestines were isolated from p53 null mice 
treated with Irinotecan and UCN-01 and analyzed by immunofluorescent 
staining for CC3 (green), pHH3 (red) and nuclei (blue, DAPI). Crypt borders 
are demarcated with white dotted lines. Scale bar = 20 µM. (b) Small 
intestines were isolated from treated mice as in panel A and the number of 
cells co-stained for CC3 and pHH3 were counted in 200-300 crypts per mouse 
per treatment group (n = 3 mice per treatment group). Data is presented as 
mean +/- SEM. Asterisks indicate significantly different using a two-tailed T-
test, *p = 0.01 to 0.05, **p = 0.01 to 0.001. (c) Small intestinal crypts 
isolated from treated mice were examined for pHH3 (red) and nuclei (blue, 
DAPI) by immunofluorescent staining. Scale bar = 100 µM. (d) The number of 
pHH3 positive cells was determined in 75 crypts per mouse (n = 3 mice per 
treatment group). Data is presented as mean +/- SEM. Asterisks indicate 
significantly different using a two-tailed T-test, *p = 0.05 to 0.01, ** p = 
0.01 to 0.001. 
Figure S4. Effects of losing both basal and induced (p53 dependent) 
p21 in crypt epithelial cells. (a) Representative image of a small intestinal 
crypt from an irinotecan-treated mouse null for both p53 and p21 stained for 
γH2AX (brown) and nuclei were counterstained with hematoxylin (blue). 
Intensity of staining was graded with 0 (no), 1 (weak), 2 (moderate) and 3 
(strong) staining. Scale bar = 50 µM. (b) The grading scale described above 
was used to score the intensity of γH2AX staining in 200-300 crypt nuclei in 
treated p53/p21 null mice (n = 3 mice per treatment group). (c) Treated 
p53/p21 null mice were injected with BrdU 30 min prior to sacrifice. Small 
intestines were isolated and analyzed by immunofluorescent staining for BrdU 
(red). Nuclei (blue) were stained with DAPI. Scale bar = 100 µM. (d) 
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Percentage of crypt epithelial cells staining positive for BrdU was determined 
by scoring 200 to 300 nuclei per mouse (n = 3 mice per treatment group). 
Data is presented as mean +/- SEM. A significant difference was not observed 
between vehicle- and irinotecan-treatment as determined by a two- tailed T-
test. (e) Parental CBRluc expressing HCT116 cells were transfected with 
control (Ctrl) shRNA (lane 1) or shRNAs targeting different regions of p21 
(lanes 2-5) followed by selection in puromycin. Lysates were prepared and 
interrogated by Western blotting. HCT116 cells null for both p21 and 14-3-3σ 
were similarly analyzed (lane 6). (f) Parental CBRluc expressing HCT116 cells 
were mock transfected (lane 1) or transfected with shRNAs targeting different 
regions of p21 (lanes 2-5). Cell lysates were prepared 48h after transfection 
and analyzed by Western blotting. Transfection with p21 shRNA #3 was run in 
duplicate. HCT116 cells null for both p21 and 14-3-3σ were similarly analyzed 
(lane 6). 
Table S1: Statistical significance for comparisons between irinotecan 
treatment across genotypes and combination treatment across 
genotypes in the intestinal crypts.  Staining and quantitation of the 
markers used was carried out as described in the main figure legends. 
Asterisks indicate significantly different as determined by a one-way ANOVA. 
*p between 0.01 and 0.05; **p between 0.01 and 0.001; ***p< 0.001. ns= 
Not significant as determined by a one- way ANOVA. 
Comparisons of irinotecan (black) and combination treatment (grey) 
across genotypes 
 
*p between 0.01 and 0.05, **p between 0.01 and 0.001, ***p< 0.001, ns= 
not significant 
Supplemental Methods 
Genotyping Trp53, Cdkn1a mutant mice 
To genotype Cdkn1a mutant mice, primers listed by the Jackson 
Laboratory were used (IMR8294, IMR8296, and IMR 0845). To genotype 
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Trp53 status in the single and double knockout lines, primers listed by the 
Jackson Laboratory were used (IMR7777, IMR7778, and IMR8306). 
Immunohistochemistry (IHC) 
Intestines were washed using a 60 ml syringe (blunt ended 181/2 gauge 
needle) filled with phosphate buffered saline (PBS). Intestines were then 
rinsed with 10% neutral buffered formalin (NBF), cut open and immobilized 
on a petridish with the villi facing upward. After overnight fixation in 10% 
NBF, sections starting with stomach and ending with the rectum were 
organized into one block by adding 1.5% agarose solution and embedded in 
paraffin. All paraffin- embedded 5 µM intestinal sections were baked in an 
oven at 65°C for 20 min and then de-paraffinized by immersing in xylene 
twice for 5 min each. The sections were then rehydrated by immersing twice 
for 2 min each in a decreasing gradient of alcohol (100%, 95% and 70% 
ethanol). Endogenous peroxidase activity was removed by incubating sections 
in 3% hydrogen peroxide in methanol for 10 min. Antigen retrieval was 
carried out by boiling sections in 10 mM sodium citrate pH 6.0 for 30 min and 
then by cooling at room temperature (RT) for an additional 30 min. Sections 
were blocked with 3% BSA/ 0.1% Tween-20/PBS (blocking solution) for 30 
min. All primary and secondary antibodies were diluted in blocking solution. 
Sections were then incubated with either serine 139 phosphorylated H2AX 
antibody (1:100, #9718) or cleaved caspase-3 antibody (1: 75) for 2h at RT 
and cleaved PARP (1:100) overnight at 4˚C (Cell Signaling Technology) 
followed by incubation with the secondary polymer-HRP anti-rabbit antibody 
(Dako). Positive staining was visualized using the HRP substrate 
Diaminobenzidine (Zymed). Sections were counterstained with Hematoxylin 
(Zymed) and then dehydrated through an increasing gradient of alcohol 
(70%, 95% and 100%) and immersed in xylene. Sections were mounted 
using cytoseal-60 (Richard Allan Scientific). 
Immunofluorescent (IF) staining 
Intestinal sections were redehydrated as described for IHC. Antigen 
retrieval was carried out as described above except 1X Rodent Decloaker 
(Biocare Medical) was used. Sections were then blocked in hydrogen peroxide 
(Dako) for 10 min and protein block (Dako) for 1h. Sections were incubated 
with the following primary antibodies diluted in antibody diluents (Dako): 
Geminin (1:350, Santa Cruz FL-209, 1.5h) and secondary polymer-HRP anti-
rabbit antibody (Dako, 30 min) followed by the fluorescein-conjugated 
Tyramide signal amplification system (1:50, Perkin Elmer, 15 min). For BrdU 
staining, anti-Brdu antibody was used (1:100, Serotec, OBT0030G) for 1.5h 
followed by Cy5-conjugated anti-rat antibody (1:100, Jackson 
ImmunoResearch). For co-staining phistone H3 and cleaved caspase-3, 
sections were incubated with phosphorylated serine 28 histone H3 (1:1000, 
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Sigma-Aldrich) and cleaved caspase-3 (1:100, Cell Signaling Technology) 
overnight at 4˚C. The following secondary antibodies were applied for 1h: 
FITC- conjugated anti-rabbit antibody (1:400, Alexis Biochemicals) for 
cleaved caspase-3 and Texas- red-conjugated anti-rat antibody (1:400, Alexis 
Biochemicals) for phistone H3. All fluorescently labeled sections were 
counterstained with 4'-6-Diamidino-2-phenylindole (DAPI) using the ProLong 
Gold antifade-DAPI reagent (Invitrogen). 
Quantitation of positive staining 
Positive staining for the initial set of treatments was measured by an 
investigator who was blinded to the identity of the treatment groups. For 
analysis of positive staining in irinotecan- UCN-01-Purvalanol/ vehicle treated 
groups; two investigators who were blinded to the identity of treatment 
groups carried out measurements. All tumor treatment sets that carried 
positive phistone H3 and cleaved caspase-3 staining were analyzed by an 
investigator who was blinded to the identity of the treatment groups. 
Cell culture and shRNA transfection 
HCT116 cells (parental, p53 null and p21/14-3-3σ null) 2,3, were 
cultured and maintained in McCoy’s 5A media (GIBCO). Sequences encoding 
CBRLuc were isolated from pCBRLuc basic vector (Promega) and sequences 
encoding EGFP were isolated from pEGFP (Clonetech). PCR strategies were 
used to clone CBRLuc and EGFP sequences into Nde I/Not1 digested pcDNA 
3.1 (Promega) to create an expression plasmid encoding the CBRLuc-EGFP 
fusion protein. HCT116 parental and derivative lines were transfected with 5 
µg of pcDNA-CBRLuc-EGFP and 12 µl of Lipofectamine 2000 (Invitrogen). 24h 
later, parental HCT116 cells were selected in media containing 10 µg/ml 
zeocin, and p53 null HCT116 cells were placed in media containing 50 µg/ml 
zeocin. ~30 drug resistant colonies were isolated and luciferase expression 
was screened by adding D-luciferin (1:100 dilution of a 30 mg/ml stock, 
Biosynth) followed by imaging using an IVIS Lumina (Caliper). For shRNA 
transfections, pLKO.1 plasmids carrying three different shRNA sequences 
were tested for their efficiency in knocking down p21 expression (shRNA #1: 
GAGCGATGGAACTTCGACTTT, shRNA#2: GCTGATCTTCTCCAAGAGGAA, 
shRNA#3: CGCTCTACATCTTCTGCCTTA). Since shRNA#3 was the most 
effective in knocking down p21 expression, it was used to carry out stable 
transfections.  shRNA targeting firefly luciferase (AGTACTTCGAAATGTCCGTT) 
was used as the control. To generate stable cell lines, cells were transfected 
with 3 µg of pLKO.1 (shRNA#3 or ctrl shRNA) plasmid and 10 μl 
Lipofectamine 2000 (Invitrogen). 48h later, cells were placed in media 
containing 2 µg/ml puromycin. ~30 colonies were screened for p21 
knockdown by Western blotting. 
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Tumor cell injections and bioluminescence imaging 
HCT116 tumor cell injections were carried out as described previously 
4, except a 29 gauge 1/2 ″ insulin syringe (Terumo) was used and 1.3x106 
cells resuspended in 30 µl DMEM were injected per site, and each mouse 
received injections at 2 distant sites in the cecum. A week after implantation, 
mice were injected with 150 mg/kg D-luciferin (Biosynth) and imaged on an 
IVIS Lumina (Caliper). Tumors from both sites were washed in PBS, and 
tumors from one site were 
formalin fixed and paraffin embedded whereas tumors from the other site 
were rapid frozen on dry ice. 
Western blotting 
Intestinal tissue (1.5 cm) was washed in PBS, finely sliced and 
resuspended in 700 µl mammalian cell lysis buffer (MCLB) and homogenized 
as previously described 5. HCT116 cells cultured on 10-cm plates were lysed 
in MCLB. Tissue and cell lysates were rocked for 20 min at 4°C and cleared at 
14,000 rpm for 10 min. Proteins were resolved by SDS-polyacrylamide gel 
electrophoresis. 150 µg of total protein was loaded per lane and transferred 
to nitrocellulose membranes (0.45 micron, Nitro Bind, GE Scientific). Blots 
were blocked overnight in 5% non fat dry milk dissolved in Tris-buffered 
saline/ 0.2% Tween-20. Blots were probed with the primary antibodies as 
indicated in the main methods. All primary antibodies were added to 5% milk 
dissolved in Tris-buffered saline/ 0.2% Tween-20. Secondary antibodies 
(Jackson ImmunoResearch) were diluted 1:30,000 in Tris-buffered 
saline/Tween-20. Blots were visualized using ECL Western blotting reagent 
(GE Scientific). 
Statistical analysis 
All graphical data is presented as mean +/- SEM. Statistically 
significant differences between various treatments are represented by 
brackets. Statistical analysis as indicated in figure legends was carried out 
either using a two-tailed t-test or one-way ANOVA using Dunnett’s multiple 
comparison post test for H2AX, pHH3, CC3 and Tukey’s multiple comparison 
post test for Geminin counting, with alpha value set to 0.05. 
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